PANC561 · LAM561 BEATS PANCREATIC CANCER
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2021-04-01 → 2023-03-31
- Финансиране от ЕС
- 160 932 €
- Участници
- 1
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Синтетичният липид LAM561 се тества върху клетъчни модели, за да се установи дали може да ограничи рака на панкреаса. Това е важно, за да се разбере механизмът на действие на веществото и да се подготвят клинични изпитвания с пациенти.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
LAM561 BEATS PANCREATIC CANCER
LAM561 BEATS PANCREATIC CANCER proposal is a translational research project introducing an innovative therapeutic approach for fighting cancer that takes advantage of inter-sectoral industry-academia strengths and international cooperation. This is also an interdisciplinary project in which lipid chemistry, cell biology, molecular biology and medicinal chemistry, meet to improve the treatment of several cancers. The beneficiary (Laminar Pharmaceuticals SA) designs and develops synthetic bio-active lipids based on cutting edge technology, Membrane Lipid Therapy (MLT), which aims to regulate the membrane lipid composition and structure to control cell functions. The company has demonstrated that the compound LAM561 (2-hydroxyoleic acid, 2OHOA) which has been designated ‘orphan drug’ by the European Medicines Agency (EMA), it has obtained a "fast track designation" by the FDA to accelerate its development and review, it has a high efficacy in the treatment of malignant brain tumors (gliomas) and it is about to finish the clinical trial phase II/III which may allow to have the product in the market by 2024. The current proposal aims to initiate the pharmaceutical development of LAM561 in order to obtain the approval to a new indication: pancreatic cancer. This project implies the challenges: 1st to extending the indications of LAM561 killer effect to pancreatic cancer and open the door to clinical trials in patients and 2nd to gain insights of LAM561 mechanism of action and promote the discovery of new MLT-based agents. Specifically, by the end of this translational project, I will have determined: Objective 1 the therapeutic potential and safety profile of LAM561 in cell models of pancreatic cancer, Objective 2 the antimigratory and antimetastatic activity in pancreatic cancer cell models, Objective 3 the antitumor safety and efficacy profile in different animal models of human and mouse pancreatic cancer and Objective 4 I will develop new MLT-based antitumor molecules against pancreatic cancer that broaden the Laminar Pharmaceuticals portfolio in oncology. LAM561 has demonstrated its efficacy against tumors like glioma, and this proposal intends to broaden the indications of this drug including data about its efficacy and safety in pancreatic cancer. The final objective of this work is to obtain the required data to advance in the development of a potential new therapy for pancreatic cancer disease. As this drug is already being developed in glioma, clinical development of the product in pancreatic cancer would be more rapid.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Pancreatic cancer is a highly aggressive type of cancer, with poor prognosis and few effective therapeutic options. At the time of diagnosis only 20% of patients are eligible for surgery, the development of metastasis has already occurred. The life expectancy of these patients is 6-11 months (stage3) or 2-6 months (stage IV). Laminar Pharmaceuticals SL is pioneer in the development of bioactive molecules that act through modulation of the lipid composition of the cell membrane regulating key signaling pathways for different pathologies, including cancer. Recently, Laminar Pharma has demonstrated the high safety and promising efficacy of its most advanced drug in clinical development, LAM561 which is being developed for the treatment of glioblastoma. The clinical study phase IIb/III of LAMP561 in glioblastoma, which evaluates the pharmacological safety of LP561 in combination with the standard treatment for this disease, is currently being completed, without observed severe adverse effects attributable to LAM561. The current project aims to carry out a preclinical study to evaluate the efficacy and safety of the anti-tumor drug LAM561 in cell and animal models of pancreatic cancer as monotherapy or in combination with standard chemotherapeutics. In addition, the study of cell migration in cell and animal models of pancreatic cancer may allow to explore the antimetastatic effect of LP561 pancreatic cancer, opening a new line of development in the company. This project aims to expand the product indications by including data on its safety and efficacy in the treatment of pancreatic cancer which requires urgent solutions. Therefore, the completion of the preclinical study would allow, at the end of the proposed studies, to launch human clinical trials to give pancreatic cancer patients the option of benefiting from this therapy more quickly. Furthermore, this represents a great opportunity which may foster the carrier of the current applicant researcher.
Оригинален текст от CORDIS (на английски).
Участници
- LAMINAR PHARMACEUTICALS SA · PALMA DE MALLORCAКоординаторИспания
Връзки
Данни: CORDIS, © Европейски съюз